Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Helius Medical Technologies Inc HSDT

Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.


NDAQ:HSDT - Post by User

Post by Swedeprofon Sep 21, 2019 11:31am
378 Views
Post# 30151389

More Testimonials

More Testimonials
3 testimonials, each are only about 1 minute. A must listen for both existing and potential shareholders. Proof IMO that the device works and that HSM/HSDT will get the FDA approval on this 2nd go around, making current share price incredibly cheap. As we wait for FDA we know that Helius will have revenues coming in and increasing quarter over quarter. Clinics are busy and more clinics are being built/converted for PoNS therapy. CE mark in Europe should come soon, and regulatory approval for Australia was also submitted for a few months ago. This will equal many more patient success stories and as a shareholder we will see increased revenue. Tori is a physiotherapist in Surrey, and this is her testimonial of the PoNS system. I found it interesting that she has been working with the PoNS since 2016, so she has a longer view of what the PoNS can do as well as experience using PoNS with more clients. https://heliusmedical.sharepoint.com/:v:/g/commercialoperations/EQ_42x3HozFEvezlWeK2r6YBut21aeM6CDEo0wGcX89nsQ?e=kQIds2 Sonia who is a clinic director https://heliusmedical.sharepoint.com/:v:/g/commercialoperations/EchbG8jWL8hJqhqteYzmsRIBZsku9-6yppIGZq9UqEe2WA?e=bcYrXS Melissa https://heliusmedical.sharepoint.com/:v:/g/commercialoperations/ERD2QYGCHNVMjM3roH562RwBpcM7ijDmw6KWZuWON7EBNQ?e=SwbKRU
Bullboard Posts